Planning a commercial launch of a biologic into the market is key to its success. In certain instances, there may be a need to get to market much faster than the typical approach. With an experienced CDMO partner, sponsor companies could take their biologic to market within just 30-45 days following regulatory approval.

In this webinar, AstraZeneca and Catalent Biologics will share a case study on a 30-day commercial launch plan for a product into new markets and why this approach was important for patients.

Key Learning Objectives:

  • Why to consider a rapid launch
  • How to plan a commercial launch and work with partners to meet critical milestones
  • Case study on rapid launch of an approved product into new markets
  • What challenges to be aware of during execution


Featured Speakers

Charlotte Lukas, MBA

External Supply Lead
AstraZeneca

Charlotte has been with AstraZeneca (previously MedImmune) since 2007. During that time, she has filled a range of roles of increasing responsibility in Operations and Biologics Process Development. Charlotte brings over 20 years of experience in biologics and vaccine manufacturing, process development, and project management to her Product Director role. She earned her Bachelor of Science degrees in Chemical Engineering and Biochemistry from Virginia Tech, a Master’s Degree in Chemical Engineering from UPenn, and an MBA from Johns Hopkins. Charlotte currently works from the Gaithersburg Maryland office.   

Amanda Henry, PMP

Sr. Project Manager
Catalent Biologics

Amanda Henry, a Senior Project Manager, has worked in the biopharma industry for more than 10 years. In her career, Amanda has managed multiple clinical and commercial projects, including process development, process performance qualification and product launches in drug product filling and packaging. She received her bachelor’s degree in management from Indiana Wesleyan University and is a certified Project Management Professional.

NOW AVAILABLE ON-DEMAND

Register now for this webinar